Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Replicel Life Sciences Inc V.RP

Alternate Symbol(s):  REPCF

Technology Scientific & Technical Instruments
RepliCel Life Sciences Inc. is a Canada-based regenerative medicine company. The Company is focused on developing cell therapies for aesthetic and orthopedic conditions, including aging/sun-damaged skin, pattern baldness, and chronic tendon degeneration. The Company’s cell therapy product pipeline is comprised of RCT-01 for tendon repair, RCS-01 for skin rejuvenation, and RCH-01 for hair... see more

Recent & Breaking News (TSXV:RP)

RepliCel Applies for Manufacturing Approval for Its Collagen and Tissue Regeneration Cell Therapies

Accesswire July 7, 2021

RepliCel Adds Independent Director

Accesswire June 15, 2021

RepliCel Launches Testing of Dermal Injector Units

Accesswire May 25, 2021

RepliCel Launches Preparations for Second Skin Rejuvenation and Tendon Regeneration Clinical Studies

Accesswire May 19, 2021

RepliCel Announces Appointment of Leading Dermatologist in Japan as Clinical Advisor

Accesswire May 17, 2021

RepliCel Launches the Next Stage of a Research Project with the University of British Columbia to Build World-Class Hair Follicle Cell Data Map

Accesswire May 11, 2021

RepliCel Announces Record Year in Patents Granted

Accesswire May 5, 2021

RepliCel Announces Appointment of Leading Sports Medicine Expert as Orthopedics Clinical Advisor (Japan)

Accesswire May 3, 2021

RepliCel Closes Second Tranche of Strategic Investment Commitment

Accesswire April 29, 2021

RepliCel Presents Its Technology Development and Commercialization Plans for Japan at Kanagawa Regenerative Medicine Industry Conference

Accesswire February 18, 2021

RepliCel Closes First Tranche of Strategic Investment Commitment

Accesswire February 10, 2021

RepliCel CEO Provides Corporate Update

Accesswire February 8, 2021

RepliCel and MainPointe Pharmaceuticals Sign Strategic Investment and Collaboration Agreement

Accesswire January 25, 2021

RepliCel Announces a Binding Term Sheet For Strategic Investment and U.S. Partnership

GlobeNewswire November 10, 2020

RepliCel Q3 2020 Management Update

GlobeNewswire September 14, 2020

RepliCel Announces its Incoming Board of Directors

Canada NewsWire December 23, 2019

RepliCel Provides 2019 Year-End Update

PR Newswire November 26, 2019

Clinical Data Published from RepliCel's Skin Rejuvenation Study

PR Newswire September 24, 2019

RepliCel's Partner, YOFOTO (China) Health, Unveils its Inaugural Cell Therapy Manufacturing Facility in China

PR Newswire September 10, 2019

RepliCel Life Sciences Retains Dermatology Sales and Marketing Executive to Guide the Global Commercial Strategy for its Automated Dermal Injector

PR Newswire August 29, 2019